OE33 Xenograft Model Service for Esophageal Adenocarcinoma (EAC)

The OE33 xenograft model is a well-established preclinical platform for evaluating therapeutic strategies against esophageal adenocarcinoma (EAC), faithfully recapitulating the histopathological and molecular features of Barrett's-associated disease progression. Alfa Cytology offers comprehensive OE33 xenograft model services, encompassing both subcutaneous and orthotopic implantation strategies, to accelerate your preclinical drug development programs with robust, reproducible tumor data and integrated pharmacodynamic endpoints.

Overview of OE33 Xenograft Model for Esophageal Adenocarcinoma (EAC)

The OE33 cell line was established in 1993 from a poorly differentiated esophageal adenocarcinoma arising in Barrett's metaplasia of a 73-year-old female patient. As an epithelial-like, adherent cell line with a doubling time of approximately 30 hours, OE33 retains key molecular hallmarks of EAC, including expression of major histocompatibility complex (MHC) class I antigens, intercellular adhesion molecule-1 (ICAM-1), and epithelial cytokeratins (CK7, CK8, CK18, CK19). Whole-genome sequencing has confirmed the presence of Barrett's-associated driver mutations, and short tandem repeat (STR) profiling has authenticated its identity against original tumor tissue, making OE33 a genetically validated model for translational research.

In vivo, OE33 demonstrates reliable tumorigenicity in immunodeficient mice, achieving 100% tumor take rates in subcutaneous xenografts and 63.6% in orthotopic models implanted in the distal esophageal wall. Histologically, OE33 tumors exhibit glandular architecture with moderate differentiation, Ki67-positive proliferative indices, and localized growth without distant metastasis. The relatively slow growth kinetics of OE33 xenografts provide an extended therapeutic window for longitudinal efficacy assessment, making this model particularly suitable for evaluating chemotherapeutic agents, targeted therapies, and combination regimens in the context of Barrett's-related esophageal adenocarcinoma.

Figure 1. IL-33 promote EAC cell proliferation through ST2. (Liu, Jia, et al., 2022)

Cell Line Information: OE33

OE33 is a human esophageal adenocarcinoma cell line derived from the primary tumor of a 73-year-old Caucasian female diagnosed with poorly differentiated adenocarcinoma associated with Barrett's metaplasia (pathological stage IIA, UICC). The cell line displays epithelial-like, adherent morphology with moderate proliferative capacity and is karyotypically characterized as a hypertetraploid aneuploid line. OE33 is microsatellite stable and has been authenticated by STR profiling according to ANSI/ATCC ASN-0002.1-2021 standards, confirming its derivation from the original patient tissue. The following table summarizes the key characteristics of the OE33 cell line:

Our Services

Alfa Cytology leverages the authenticated OE33 cell line to deliver standardized, high-fidelity xenograft models with comprehensive in-life monitoring, tumor volume tracking, and multi-parameter endpoint analysis, ensuring your preclinical EAC research program receives reliable, publication-ready data from study initiation through final reporting.

Workflow of OE33 Xenograft Model Construction

The construction of OE33 xenograft models follows a rigorous, standardized workflow that ensures reproducible tumor establishment and high-quality data generation. Both subcutaneous and orthotopic implantation routes are available, with the latter requiring surgical expertise to replicate the anatomical tumor microenvironment of esophageal adenocarcinoma. The workflow encompasses cell line authentication, recipient mouse preparation, tumor cell implantation, in-life monitoring, and terminal endpoint analysis.

1. Cell Line Expansion and Quality Control: OE33 cells are expanded from authenticated cryopreserved stocks under standard culture conditions (RPMI 1640 + 10% FBS, 37 degrees C, 5% CO2). Prior to implantation, cells undergo viability assessment (typically >95% viability required), mycoplasma testing, and STR confirmation to ensure genetic integrity.
2. Recipient Animal Preparation: Immunodeficient nude mice (athymic nu/nu) or NOD-SCID mice are acclimatized for one week under pathogen-free conditions. Animals are randomized by body weight and ear-tagged for individual identification. Pre-implantation baseline measurements, including body weight and general health assessment, are recorded.
3. Tumor Cell Preparation: Exponentially growing OE33 cells are harvested using trypsin-EDTA, washed in sterile PBS, and resuspended in a 1:1 mixture of serum-free medium and Matrigel at a concentration of 5x10^6 to 1x10^7 cells per 100 microL. The cell suspension is kept on ice to maintain Matrigel integrity until injection.
4. Subcutaneous Implantation: For subcutaneous xenografts, 100 microL of the OE33 cell suspension is injected into the right flank using a 25-gauge needle. Tumor engraftment is monitored by palpation three times weekly, with caliper measurements initiated once tumors become palpable (typically 7-14 days post-injection).
5. Orthotopic Implantation: For orthotopic models, mice undergo median laparotomy under general inhalation anesthesia. The distal esophageal wall is exposed, and 30 microL of OE33 cell suspension is injected through a 30-gauge needle into the submucosal layer, creating a visible bleb. The abdominal wall is closed in layers, and post-operative analgesia is administered according to IACUC guidelines.
6. In-Life Monitoring and Tumor Measurement: Tumor dimensions are measured with digital calipers three times weekly, and volumes are calculated using the modified ellipsoid formula (V = 0.5 x length x width^2). Body weight, clinical signs, and tumor burden are recorded in a secure electronic data capture system. MRI or ultrasound imaging may be employed for orthotopic tumor visualization.
7. Endpoint Analysis and Tissue Collection: Upon reaching predetermined endpoint criteria (typically tumor volume of 1,500-2,000 mm^3 for subcutaneous models, or 8-10 weeks for orthotopic studies), animals are humanely euthanized. Tumors are excised, weighed, and processed for histopathology (H&E, Ki67), immunohistochemistry, biomarker analysis, and pharmacodynamic assessment.

Figure 2: Schematic workflow illustrating the derivation and construction of the OE33 Xenograft Model at Alfa Cytology.

Case Study-OE33 Xenograft Model Development

In a representative preclinical evaluation, OE33 xenografts were established in immunodeficient mice to assess the efficacy of a novel therapeutic candidate targeting the EGFR/HER2 signaling axis. Subcutaneous implantation achieved 100% tumor take with consistent growth kinetics, enabling robust statistical powering for treatment cohorts. Treatment groups received the investigational compound via intraperitoneal administration on a biweekly schedule for four weeks, while control animals received vehicle only. Tumor growth inhibition was quantified through serial caliper measurements, with terminal analysis revealing significant reductions in tumor volume and Ki67 proliferative index in treated animals compared to controls. Comprehensive pharmacodynamic profiling, including Western blot analysis of downstream signaling mediators and plasma biomarker assessment, provided mechanistic insights into compound activity. This case study demonstrates the utility of the OE33 model in generating reproducible, mechanism-driven preclinical data to support IND-enabling studies and clinical trial design for esophageal adenocarcinoma therapeutics.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational excellence to deliver OE33 xenograft models that meet the highest standards of preclinical research. Our integrated service platform ensures seamless study execution from model development through data delivery, with dedicated project management and transparent communication at every stage.

• Authenticated cell lines with verified STR profiles and documented tumorigenicity ensure genetic fidelity and reproducible tumor establishment.
• Dual implantation expertise in both subcutaneous and orthotopic OE33 models provides flexibility to match your specific research objectives and compound characteristics.
• Comprehensive in-life monitoring with electronic data capture, digital caliper measurements, and optional advanced imaging (MRI/ultrasound) delivers high-resolution longitudinal datasets.
• Integrated pharmacodynamic and biomarker analysis capabilities, including histopathology, immunohistochemistry, and molecular profiling, generate mechanism-driven endpoint data.
• Customizable study designs with flexible dosing schedules, combination therapy arms, and adaptive endpoint criteria accommodate diverse therapeutic modalities and development stages.
• Regulatory-compliant quality systems and IACUC-approved protocols ensure ethical standards and data integrity suitable for IND-enabling packages and regulatory submissions.

Contact Us

Ready to advance your esophageal adenocarcinoma research program? Please reach out to us today via our inquiry form or email to learn more about our OE33 Xenograft Model services.

For research use only. Not intended for any clinical use.